Market Cap (In SEK)
677.79 Million
Revenue (In SEK)
137 Thousand
Net Income (In SEK)
-95.5 Million
Avg. Volume
4.71 Million
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.1136-0.435
- PE
- -
- EPS
- -
- Beta Value
- 1.264
- ISIN
- SE0002575340
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Ellen K. Donnelly Ph.D.
- Employee Count
- -
- Website
- https://abliva.com
- Ipo Date
- 2008-10-03
- Details
- Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
More Stocks
-
BSQKZBlock, Inc.
BSQKZ
-
CDP
-
PAAL-BPer Aarsleff Holding A/S
PAAL-B
-
4584
-
ESTA
-
271940Iljin Hysolus Co., Ltd.
271940
-
EPR-PCEPR Properties
EPR-PC
-
MIRG